Get the app
US › Healthcare

Tectonic Therapeutic, Inc. (TECX)

US · Healthcare · Biotechnology

$20.64+6.28%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-22.3M
EPS
$-1.18
EPS estimate
$-1.41

EPS came in at -1.18 against a street estimate of -1.41 — a beat of 16.3%.

Key statistics

Market cap
$379.6M
Forward P/E
0.0
P/B
1.66
Book value
$11.64
EPS (TTM)
$-4.57
52-week high
$39.53
52-week low
$16.77
50-day MA
$24.94
200-day MA
$28.09
Beta
0.50

Analyst view

Analysts rate Tectonic Therapeutic, Inc. a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $71.00.

Shareholding

Insiders
37.65%
Institutions
69.05%

Largest institutional holders

FundStake
FMR Inc14.48%
TCG Crossover Management, LLC6.16%
Aberdeen Group PLC5.84%
BlackRock Inc4.41%
First Light Asset Management, LLC4.10%
Baker Bros Advisors LP3.11%
5AM Venture Management, LLC3.10%
BRAIDWELL LP3.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tectonic Therapeutic, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.